ClinicalTrials.gg

Program

azirkitug

In AbbVie's pipeline, CCR8. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by AbbVie.

Furthest: phase 1, since Aug 12, 20211 company-led study, 1 open or runningNext primary completion: Jul 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie11 open or runningphase 1since Aug 12, 2021Aug 12, 2021Jul 2027phase 1 · NCT05005403
  • Named in AbbVie’s own pipeline as Azirkitig (ABBV-514), phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 12, 2021First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05005403 · 694 planned · United States, Canada, Israel and more

Ahead

  1. Jul 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT05005403

TargetBeta

“CCR8”the company's pipeline, read by Claude · source

Other programs on CCR8

ProgramCompanyFurthest phaseStudies
cafelkibartSino Biopharmaceuticalphase 37
CCR8 Inhibitor IPG7236rulenanjing-immunophage-biotech-co-ltdphase 23
denikitugruleGilead Sciencesphase 23
imzokitugBristol-Myers Squibbphase 22
Anti-CCR8 Antibody-drug Conjugate TAK-188ruleTakedaphase 21
Anti-CCR8 Monoclonal Antibody HC006rulehc-biopharma-incphase 12

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05005403Carcinoma, Non-Small-Cell Lung · United States, Canada, Israel and more1RecruitingJul 2027694

How it is read

Names in the registry

  • “Azirkitug”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.